NCT03535961View on ClinicalTrials.gov

Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

May 1, 2019

Study Completion Date

May 1, 2019

Conditions
Breast Cancer
Interventions
DRUG

apatinib+oral etoposide

apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle

Trial Locations (1)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Chinese Academy of Medical Sciences

OTHER

NCT03535961 - Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer | Biotech Hunter | Biotech Hunter